4.8 Article

Crosstalk between histone modifications indicates that inhibition of arginine methyltransferase CARM1 activity reverses HIV latency

Journal

NUCLEIC ACIDS RESEARCH
Volume 45, Issue 16, Pages 9348-9360

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkx550

Keywords

-

Funding

  1. Creative and Novel Ideas in HIV Research (CNIHR) program from National Institutes of Health (NIH)
  2. NIH [R21AI122418]
  3. Cancer Prevention Research Institute of Texas (CPRIT) [RP110784]
  4. American Cancer Society [RSG-13-061-01]
  5. Baylor College of Medicine: the CFAR core [NIH P30 AI036211]
  6. Cytometry and Cell Sorting Core [NIH P30 AI036211, P30 CA125123, S10 RR024574]

Ask authors/readers for more resources

In eukaryotic cells, the gene expression status is strictly controlled by epigenetic modifications on chromatin. The repressive status of chromatin largely contributes to HIV latency. Studies have shown that modification of histone H3K27 acts as a key molecular switch for activation or suppression of many cellular genes. In this study, we found that K27-acetylated histone H3 specifically recruited Super Elongation Complex (SEC), the transcriptional elongation complex essential for HIV-1 long terminal repeat (LTR)-mediated and general cellular transcription. Interestingly, H3K27 acetylation further stimulates H3R26 methylation, which subsequently abrogates the recruitment of SEC, forming a negative feedback regulatory loop. Importantly, by inhibiting methyltransferase activity of CARM1, the enzyme responsible for H3R26 methylation, HIV-1 transcription is reactivated in several HIV latency cell models, including a primary resting CD4+ T cell model. When combined with other latency disrupting compounds such as JQ1 or vorinostat/SAHA, the CARM1 inhibitor achieved synergistic effects on HIV-1 activation. This study suggests that coordinated and dynamic modifications at histone H3K27 and H3R26 orchestrate HIV-1 LTR-mediated transcription, and potentially opens a new avenue to disrupt latent HIV-1 infection by targeting specific epigenetic enzymes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available